Company news
Innocare Pharma Ltd. Class A (SSE:688428) news
Every Innocare Pharma Ltd. Class A press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Announcement on Adjusting the Nomination Committee Members of the Board of Directors
November 13, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 5, 2025
InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
October 29, 2025
Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025
October 28, 2025
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
October 8, 2025
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
September 6, 2025
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China
August 21, 2025
Announcement on Grant of Reserved Restricted Shares to Grantees
August 20, 2025
InnoCare Releases 2025 Interim Results and Business Highlights
August 19, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 11, 2025
Announcement on Vesting Results of the 2nd Vesting Period of Those Initially Granted and the 1st Vesting Period of Those Reserved for Grant in 2023 STAR Market Restricted Stock Incentive Plan and Listing of Shares
July 15, 2025
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
July 3, 2025
Announcement on Resolution of the Board of Directors
June 20, 2025
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%
June 19, 2025
Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress
June 12, 2025
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
June 1, 2025
Announcement on the Cash Management Using Some Temporarily Idle Raised Funds and Deposit of Raised Funds through Call Deposits and Agreement Deposits
May 29, 2025
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
May 28, 2025
InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
May 21, 2025
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China
May 16, 2025
Announcement on Signing Strategic Cooperation Framework Agreement and Scientific Research Cooperation Agreement with Westlake University and Related Party Transactions
May 13, 2025
InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA
May 11, 2025
Announcement on the Provision of Online Voting Reminder Service for the General Meeting
May 6, 2025
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
May 1, 2025
Notice on Convening the 2025 Annual General Meeting
April 28, 2025
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China
April 25, 2025
InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China
April 15, 2025
Announcement on Voluntary Disclosure of the Latest Research Results of Multiple Oncology Pipelines Selected for 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 8, 2025
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
March 27, 2025
InnoCare Releases 2024 Results and Business Highlights
March 27, 2025
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China
March 20, 2025
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
March 9, 2025
Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum
February 26, 2025
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
February 17, 2025
Announcement on Appointment of Independent Non-executive Director
January 21, 2025
Announcement on Signing License Agreement for CD20*CD3 Bispecific Antibody (ICP-B02/CM355) between Subsidiary and Prolium
January 20, 2025
Annual Earnings Preannouncement for 2024
January 16, 2025
Indicative Announcement on the Postponement of By-election for Independent Non-executive Director
December 24, 2024
Announcement on the First Granting of Restricted Stocks to Incentive Objects
December 17, 2024
Notice on the Review Opinions and Remarks on Publicity of Lis of Incentive Recipients List for the Initial Grant of the 2024 SSE STAR Market Restricted Stock Incentive Plan
December 9, 2024
Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2024
November 28, 2024
Summary Announcement on the 2024 STAR Market Restricted Stock Incentive Plan (Draft)
November 26, 2024
The Q3 2024 Report
November 11, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 4, 2024
Announcement on Voluntary Disclosure of Phase II Clinical Trial Result of ICP-488
October 9, 2024
Announcement on the Resignation of Non-executive Directors and Independent Non-executive Directors and the Change of Members of Special Committees of the Board of Directors
September 25, 2024
Announcement on Change of Sponsor Representative for Continuous Supervision
September 20, 2024
Announcement on Listing and Circulation of Initial Public Offering of Strategic Placement Restricted Shares
September 10, 2024
Announcement on Voluntary Disclosure of Clinical Trial Progress of Aobrutinib
September 8, 2024
Semi-annual Report in 2024
August 20, 2024